87
Participants
Start Date
May 25, 2018
Primary Completion Date
September 26, 2023
Study Completion Date
November 15, 2031
Carfilzomib
56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
Lenalidomide
"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
Daratumumab
16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
Dexamethasone
40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
Weill Cornell Medicine, New York
University of Maryland Medical Center, Baltimore
Levine Cancer Institute, Charlotte
Moffitt Cancer Center, Tampa
Indiana University Simon Cancer Center, Indianapolis
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
University of Chicago Medical Center, Chicago
University of Kansas Cancer Center, Westwood
Swedish Cancer Institute, Seattle